Related Experiment Videos
A Magnetic Bead-Based Negative Selection and Flow Cytometry Protocol for Evaluating Licochalcone A-Mediated
Xue Jiang1, Fujin Yang1, Guoyi Yan2
1Chongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine.
Abstract:
Naïve CD4⁺ T cell differentiation into Th17 cells is a key driver of autoimmune and chronic inflammatory skin diseases. Licochalcone A (Lico-A), a bioactive flavonoid from Glycyrrhiza inflata, exhibits anti-inflammatory activity in dermatological applications, yet its direct effect on Th17 commitment remains poorly characterized due to a lack of standardized evaluation protocols. To address this, this protocol establishes a complete in vitro workflow to assess Lico-A's inhibition of naïve CD4⁺ T cell differentiation into Th17 cells. The procedure comprises: isolation of highly pure naïve CD4⁺ T cells from mouse spleens via magnetic bead-based negative selection (>90% purity); induction of Th17 polarization under anti-CD3/CD28 costimulation with a defined cytokine cocktail (TGF-β, IL-6, IL-1β, IL-23, and IL-2, supplemented with anti-IL-4 and anti-IFN-γ); treatment with 500 nM Lico-A throughout the 72-hour polarization period; and quantification of differentiation efficiency by intracellular IL-17A staining followed by flow cytometric analysis. Critical controls, including parallel cell viability staining, are incorporated to distinguish specific inhibition of differentiation from nonspecific cytotoxicity. In a representative experiment, Lico-A reduced the proportion of CD4⁺IL-17A⁺ cells from 45.8% to 11.5% without compromising cell viability. This standardized protocol offers a reproducible platform for screening immunomodulatory compounds and investigating their mechanisms in Th17-associated inflammatory skin diseases. However, disease-relevant therapeutic effects require validation in appropriate in vivo animal models.